Ignite Creation Date:
2025-12-25 @ 12:31 AM
Ignite Modification Date:
2026-01-23 @ 1:05 PM
Study NCT ID:
NCT02843867
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2022-08-03
First Post:
2016-07-08
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Orientation of the Lymphocyte Response to the Occurrence of Atherosclerotic Complications After Kidney Transplantation
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D050197', 'term': 'Atherosclerosis'}], 'ancestors': [{'id': 'D001161', 'term': 'Arteriosclerosis'}, {'id': 'D001157', 'term': 'Arterial Occlusive Diseases'}, {'id': 'D014652', 'term': 'Vascular Diseases'}, {'id': 'D002318', 'term': 'Cardiovascular Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D001800', 'term': 'Blood Specimen Collection'}], 'ancestors': [{'id': 'D013048', 'term': 'Specimen Handling'}, {'id': 'D019411', 'term': 'Clinical Laboratory Techniques'}, {'id': 'D019937', 'term': 'Diagnostic Techniques and Procedures'}, {'id': 'D003933', 'term': 'Diagnosis'}, {'id': 'D011677', 'term': 'Punctures'}, {'id': 'D013514', 'term': 'Surgical Procedures, Operative'}, {'id': 'D008919', 'term': 'Investigative Techniques'}]}}, 'protocolSection': {'designModule': {'bioSpec': {'retention': 'SAMPLES_WITHOUT_DNA', 'description': 'Serum Peripheral Blood Mononuclear Cells'}, 'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'PROSPECTIVE', 'observationalModel': 'COHORT'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 1150}, 'patientRegistry': False}, 'statusModule': {'overallStatus': 'ACTIVE_NOT_RECRUITING', 'startDateStruct': {'date': '2008-11-28', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2022-07', 'completionDateStruct': {'date': '2030-10-23', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2022-08-01', 'studyFirstSubmitDate': '2016-07-08', 'studyFirstSubmitQcDate': '2016-07-21', 'lastUpdatePostDateStruct': {'date': '2022-08-03', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2016-07-26', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2020-10-23', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Percentage of regulatory T cells related to atherosclerotic complications events.', 'timeFrame': '5 or 10 years', 'description': 'Percentage of regulatory T cells'}], 'secondaryOutcomes': [{'measure': 'Atherosclerotic complications events', 'timeFrame': '5 or 10 years', 'description': 'Percentage of regulatory T cells'}, {'measure': 'Genetic determinants (TNF-alpha, IL-6,...) related to cardiovascular events', 'timeFrame': '5 or 10 years', 'description': 'Percentage of regulatory T cells'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'keywords': ['Transplantation', 'Immunology', 'Atherosclerosis'], 'conditions': ['Disorder Related to Renal Transplantation']}, 'referencesModule': {'references': [{'pmid': '31515130', 'type': 'DERIVED', 'citation': 'Ducloux D, Courivaud C, Bamoulid J, Crepin T, Gaiffe E, Laheurte C, Vauchy C, Rebibou JM, Saas P, Borot S. Immune phenotype predicts new onset diabetes after kidney transplantation. Hum Immunol. 2019 Nov;80(11):937-942. doi: 10.1016/j.humimm.2019.08.006. Epub 2019 Sep 10.'}, {'pmid': '30026783', 'type': 'DERIVED', 'citation': 'Ducloux D, Legendre M, Bamoulid J, Rebibou JM, Saas P, Courivaud C, Crepin T. ESRD-associated immune phenotype depends on dialysis modality and iron status: clinical implications. Immun Ageing. 2018 Jul 17;15:16. doi: 10.1186/s12979-018-0121-z. eCollection 2018.'}]}, 'descriptionModule': {'briefSummary': 'The incidence of atherosclerotic complications is increased after kidney transplantation. Traditional risk factors do not fully explain this increased risk. Atherosclerosis is an inflammatory disease in which all players in the immune response are involved. The impact of these immune responses is not well known in immunocompromised patients, particularly among organ transplant. Nevertheless, the work of our group suggest that innate and acquired responses through different mechanisms influencing the evolution of atheromatous disease after transplantation.\n\nThe investigators therefore propose to study the impact of the expansion of regulatory T cells on the risk of atherosclerotic complications after transplantation.\n\nSince November 2008, the investigators began a multicenter, prospective study whose purpose is to study in detail the immunological mechanisms of atherosclerosis after transplantation via immunomonitoring cohort of renal transplant patients in the Grand East Interregion. It was planned to include 500 patients and to date a little more than half have been included. After completion of the blood test, the tubes are routed over the Biomonitoring Platform (CIC-BT 506 Besançon) and the samples are stored in CRB Dijon.\n\nThe atherosclerotic events are recorded prospectively. The investigators hope to implement as part of ORLY IS, a second study to determine the impact of an expansion of regulatory T cells on the risk of atherosclerotic events.\n\nOur hypothesis is that a cell rate regulatory T below the median results in an increase of 5% of atherosclerotic complications.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'samplingMethod': 'PROBABILITY_SAMPLE', 'studyPopulation': 'The study population corresponds to 1000 patients receiving a renal transplant in Hospital of Besançon, Dijon, Nancy, Reims, Clermont-Ferrand, Strasbourg et Kremlin-Bicêtre.', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. Male or female patients aged over 18 years\n2. Patients receiving a renal transplant\n3. Patients able to understand the benefits and risks of testing\n4. Patients gave written informed consent.\n\nExclusion Criteria:\n\n1. Inability to understand the advantages and disadvantages of the study; psychiatric disorders judged by the investigator to be incompatible with the inclusion in the study.\n2. Immunosuppressive therapy immediately prior to transplantation\n3. Cancer (except skin cancer) or malignant blood disease being treated; active infection; decompensated cirrhosis \\[patients had cancer and considered as cured or in remission, patients with virus infection of hepatitis B or hepatitis C and having no cirrhosis may be included\\].\n\nThis study is strictly non-interventional, participation in another study is not a cons-indication to the inclusion in this study and no exclusion period is required for inclusion in another study after inclusion in this study (Art L. 1121-12 (loi n°2004-806 du 9 Août 2004).'}, 'identificationModule': {'nctId': 'NCT02843867', 'acronym': 'ORLY-Est', 'briefTitle': 'Orientation of the Lymphocyte Response to the Occurrence of Atherosclerotic Complications After Kidney Transplantation', 'organization': {'class': 'OTHER', 'fullName': 'Centre Hospitalier Universitaire de Besancon'}, 'officialTitle': "Influence de l'ORientation de la réponse LYmphocytaire Sur la Survenue de Complications athéromateuses après Transplantation rénale (étude ORLY-EST 2)", 'orgStudyIdInfo': {'id': 'R/2011/44'}}, 'armsInterventionsModule': {'interventions': [{'name': 'blood sample', 'type': 'OTHER', 'description': '36 ml of blood sample at D0 and 1 year after transplantation'}]}, 'contactsLocationsModule': {'locations': [{'zip': '25000', 'city': 'Besançon', 'country': 'France', 'facility': 'CHU de Besançon', 'geoPoint': {'lat': 47.24878, 'lon': 6.01815}}, {'zip': '63003', 'city': 'Clermont-Ferrand', 'country': 'France', 'facility': 'CHU Clermont-Ferrand, 58 rue Montalembert, 63003 Clermont-Ferrand', 'geoPoint': {'lat': 45.77969, 'lon': 3.08682}}, {'zip': '21079', 'city': 'Dijon', 'country': 'France', 'facility': 'CHU Dijon, Hôpital du Bocage, 2 Bd du Maréchal de Lattre de Tassigny, 21079 Dijon cedex', 'geoPoint': {'lat': 47.31344, 'lon': 5.01391}}, {'zip': '94275', 'city': 'Le Kremlin-Bicêtre', 'country': 'France', 'facility': 'Hôpital du Kremlin Bicêtre 78, rue du Général Leclerc, 94275 Le Kremlin-Bicêtre Cedex', 'geoPoint': {'lat': 48.81471, 'lon': 2.36073}}, {'city': 'Nancy', 'country': 'France', 'facility': 'CHU Brabois, et Vandoeuvre les Nancy', 'geoPoint': {'lat': 48.68439, 'lon': 6.18496}}, {'zip': '51092', 'city': 'Reims', 'country': 'France', 'facility': 'CHU Reims, 45 rue Cognacq-Jay 51092 Reims Cedex', 'geoPoint': {'lat': 49.26526, 'lon': 4.02853}}, {'zip': '67091', 'city': 'Strasbourg', 'country': 'France', 'facility': "Hôpital Civil- 1, place de l'hôpital BP426 ; 67091 Strasbourg Cedex", 'geoPoint': {'lat': 48.58392, 'lon': 7.74553}}], 'overallOfficials': [{'name': 'Didier Ducloux, Pr.', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'CHRU de Besançon'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'YES', 'description': 'Identified individual participant data for all outcome measures will be made available within 6 monts of study completion'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Centre Hospitalier Universitaire de Besancon', 'class': 'OTHER'}, 'collaborators': [{'name': 'University of Franche-Comté', 'class': 'OTHER'}, {'name': 'Etablissement Français du Sang', 'class': 'OTHER'}], 'responsibleParty': {'type': 'SPONSOR'}}}}